SCHEMBL23201987

SCHEMBL23201987

CC1(C)Oc2cccnc2N(Cc2ncc(C(=O)NO)cc2F)C1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 16/20 0.45
▸ HDAC1 Q13547 6/20 0.40
▸ HDAC8 Q9BY41 3/20 0.39
▸ HDAC3 O15379 2/20 0.39
▸ HDAC4 P56524 2/20 0.39
▸ HDAC7 Q8WUI4 2/20 0.39
▸ HDAC10 Q969S8 2/20 0.39
▸ HDAC11 Q96DB2 2/20 0.39
▸ HDAC9 Q9UKV0 2/20 0.39
▸ HDAC5 Q9UQL6 2/20 0.39
▸ POLB P06746 1/20 0.37
▸ HDAC2 Q92769 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ PLK4 O00444 1/20 0.33
▸ AURKA O14965 1/20 0.33
▸ STK16 O75716 1/20 0.33
▸ LATS1 O95835 1/20 0.33
▸ RET P07949 1/20 0.33
▸ FLT3 P36888 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25138358 0.75 HDAC6 (0.49) HDAC6HDAC1HDAC8HDAC3HDAC4
SCHEMBL29779602 0.71 CHRM1 (0.49) HDAC6HDAC1HDAC8HDAC5POLB
SCHEMBL23166446 0.71 CHRM1 (0.49) HDAC6HDAC1HDAC8HDAC5POLB
SCHEMBL23202566 0.69 HDAC6 (0.43) HDAC6HDAC1HDAC8HDAC3HDAC4
SCHEMBL23201985 0.68 SLC22A12 (0.44) HDAC6HDAC1HDAC8HDAC3HDAC4
SCHEMBL23201965 0.68 HDAC6 (0.52) HDAC6HDAC1HDAC8HDAC3HDAC4
SCHEMBL23202570 0.68 PTGDR2 (0.44) HDAC6HDAC1HDAC8HDAC3HDAC4
SCHEMBL23202576 0.67 HDAC6 (0.43) HDAC6HDAC1HDAC8HDAC3HDAC4
SCHEMBL12904005 0.66 HDAC6 (0.48) HDAC6ALDH1A1
SCHEMBL25138325 0.66 HDAC6 (0.54) HDAC6HDAC1HDAC8HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230381148-A1 HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF TENAYA THERAPEUTICS, INC. 2023-11-30 — — US disclosed
US-20230381148-A1 HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF TENAYA THERAPEUTICS, INC. 2023-11-30 — — US disclosed
US-20230123856-A1 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF TENAYA THERAPEUTICS, INC. (US) 2023-04-20 — — US disclosed
WO-2021067859-A1 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF TENAYA THERAPEUTICS, INC. (US) 2021-04-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230381148-A1 HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF HDAC6, HDAC1, HDAC2 HDAC6 1/4885HDAC1 2/4885HDAC8 12/4885
US-20230123856-A1 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF SLC28A1, SLC5A1, SLC9A5 HDAC6 40/4885HDAC1 60/4885HDAC8 352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback